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Abstract
The human immunodeficiency virus (HIV) epidemic continues to spread and evolve on a worldwide basis. Currently more than five 
million patients in South Africa are living with HIV/AIDS. Cutaneous and mucosal complications eventually occur in nearly all individu-
als with HIV infection, and can be debilitating, disfiguring, and life-threatening. Their incidence increases with deteriorating immune 
function. Familiarity with cutaneous disease patterns in this population enables early diagnosis and institution of correct treatment, 
detection of unrecognised HIV infection or progression to the acquired immunodeficiency syndrome (AIDS), and, counselling and 
prevention of further transmission. Knowledge of the skin and mucosal signs of HIV/AIDS is important. 
 This article has been peer reviewed. Full text available at www.safpj.co.za SA Fam Pract 2008;50(6):14-23
Introduction
Patients may present with skin and mucosal signs or they may develop 
during the course of the illness. Skin signs give an indication of the 
degree of immunodeficiency and prognosis of the patient and also form 
an integral component of the WHO staging system.  Skin signs are a 
common component of drug reactions and the immune reconstitution 
and inflammation (IRIS) syndrome. The diagnosis of skin and mucosal 
conditions is often difficult.  Patients may present with atypical signs, 
double and triple pathology are common, a single aetiologic agent may 
cause diverse clinical features, diverse aetiologic agents may cause a 
single morphological presentation, patients are often receiving multiple 
medications, drug interactions may occur, new conditions are regularly 
published, and cases are seen with new unpublished manifestations. 
Atypical presentation refers to unusual distribution and morphology 
of lesions, resistance to treatment and recurrence following adequate 
treatment.  
The number of T-helper lymphocytes (CD4 count) is a useful 
measure of a patient’s immunocompetence or, by inference, disease 
progression. A healthy person has a CD4 count of 1200–1400. The 
declining CD4 count often is associated with the appearance of 
certain cutaneous conditions (Table I). Zidovudine prophylaxis may 
be initiated when the CD4 count drops below 500 and Pneumocystis 
jiroveci pneumonia prophylaxis when the CD4 count reaches 200 or 
below. However, it is not uncommon to treat a patient with a CD4 cell 
count of less than 20 who has experienced none of these disorders. 
Nonetheless, in patients with HIV infection, a CD4 cell count below 200 
correlates with a number of skin conditions, including severe systemic 
and cutaneous infections caused by viruses, bacteria, parasites or 
fungi.
Primary HIV infection
Two to four weeks after inoculation with HIV-1, with high levels of 
circulating infectious virions, a symptomatic seroconversion reaction 
occurs in 50 to 70% of individuals. Arthralgia, myalgia, fever, weight 
loss, nausea, vomiting and diarrhoea and lymphadenopathy are 
present.  Neurological manifestations include aseptic meningitis, 
encephalitis and neuropathy.  A cutaneous eruption is present in 
approximately 75% of cases and is characterised by a widespread, non 
pruritic morbilliform rash which typically fades within one to two weeks. 
Urticarial and vesicular lesions have been described.  Alopecia may 
develop.  Erythema multiforme and acute erosive genitocrural intertrigo 
have been described.  Histology in all instances is nonspecific and 
does not give a clue of the underlying HIV infection.  Mucocutaneous 
ulceration involving the oropharynx, oesophagus, or anogenital area 
is common. Severe primary HIV infection may be associated with 
oropharyngeal or oesophageal candidiasis. Illness lasting more than 
two weeks is associated with an eight times higher risk of developing 
AIDS within three years after seroconversion. 
Diagnosis of HIV seroconversion is made by detection of p24 antigen, 
appearing within days of infection; detection of HIV-specific antibodies, 
appearing within the first few weeks of onset of the acute illness; or 
isolation of HIV by culture or by HIV DNA or RNA PCR.
Condition CD4 Count 
Seborrhoeic dermatitis    500 
Onychomycosis    450 
Oral hairy leukoplakia    400 
Herpes zoster    400 
Oral candidiasis    300 
Molluscum contagiosum    250 
Tuberculosis < 200 
Cutaneous anergy < 200 
Eosinophilic folliculitis    100 
Mycobacterium avium 
intracellulare 
     50 
Resistant herpes simplex      50 
Table I: Correlation between disease occurrence and CD4 counts 
Modified from Reference 1 
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Cutaneous manifestations of HIV-disease are numerous (Table II). 
Only twelve conditions will be discussed in more detail. The treatment 
of these conditions, the influence of antiretroviral treatment, and IRIS 
will not be addressed comprehensively. 
Table II: Cutaneous manifestations of HIV infection 
Cancers  Viral infections
Kaposi’s sarcoma Molluscum contagiosum
Lymphomas (B-cell) Herpes simplex (chronic/disseminated)
Basal cell carcinoma Zoster
Melanoma, dysplastic nevi Varicella 
Arthropod infections EBV-related rash
Scabies (crusted) Oral hairy leukoplakia
Protozoal infections Warts 
Amoebiasis Cytomegalovirus infection 
Fungal infections Disorders of hair and nails
Candidiasis Leukonychia, nail deformity, yellow-nail syndrome
Dermatophytosis Alopecia areata




Pneumocystosis Dry skin, ichthyosis
Sporotrichosis Manifestations of nutritional deficiency
Scopulariopsis Eosinophilic folliculitis





Cellulitis Precocious skin aging
Mycobacteriosis Bullous pemphigoid




Papulosquamous diseases Lichen planus
Seborrhoeic dermatitis Papular mucinosis
Psoriasis, Reiter’s syndrome Neutrophilic eccrine hidradenitis
Pityriasis rosea Eruptive dermatofibroma
Worsening of Urticaria, pruritus and prurigo
Infections (e.g. syphilis, scabies) Photosensitivity










Modified from Reference 2
1.     Staphylococcus aureus infections 
Staphylococcus aureus is the most common cutaneous and systemic 
bacterial pathogen in HIV-infected adults. Increased nasal carriage, 
an impaired cutaneous barrier, decreased numbers of, and ineffective 
neutrophils, as well as pruritus and scratching contribute to the 
development of pyoderma. Cutaneous infection correlates with 
advancing immunodeficiency and can manifest as impetigo, ecthyma, 
folliculitis (Figure 1), furunculosis, abscesses, staphylococcal scalded 
skin syndrome or cellulitis. Impetigo appears as chronic, crusted 
erosions of the head or neck, or atypical bullous lesions of the axillae or 
groins. Folliculitis is often pruritic and accompanied by eczematisation. 
The denouement of folliculitis is very difficult.  In the differential 
diagnosis herpes simplex folliculitis, varicella/zoster folliculitis, 
dermatophyte folliculitis, candida folliculitis, malassezial folliculitis, 
demodex folliculitis and eosinophiliic folliculitis must be considered.  
S aureus may also cause secondary infection of underlying atopic 
dermatitis, scabies, herpetic ulcers, or Kaposi’s sarcoma. Infection 
of indwelling venous catheters is common, and is associated with 
significant morbidity. Unusual clinical patterns of infection may occur 
such as botryomycosis, a chronic suppurative infection with grains 
in the purulent material, and atypical plaque like lesions of the scalp, 
axilla and groin. These lesions are refractory to treatment.  Methicillin-
resitant Staphylococcus aureus may present particular problems.  
Cutaneous bacterial infection in HIV-infected patients poses the risk 
of bacteraemia and septicaemia.  The clinician must be alert to the 
dermatological sings of systemic bacterial infection such as splinter 
haemorrhages and acral papulonecrotic lesions.  
Figure 1:  Widespread staphylococcal folliculitis
A high index of suspicion and a low threshold for performing 
microbiological investigations (Gram stains and cultures) and skin 
biopsies is important to enable precise diagnosis and institution of 
prompt treatment.  
Patients should be treated with oral dicloxacillin and topical mupirocin, 
or intravenous nafcillin if cellulitis is present. Eradication of the carrier 
state can be achieved by applying mupirocin ointment to the nares, 
chlorhexidine gluconate solution for washing, and oral rifampin. 
2.  Dermatophytoses
 Dermatophytes infect keratinised skin, hair, and nails. Superficial fungal 
infection in HIVdisease can have an atypical clinical presentation and 
may be extensive, recurrent, and difficult to treat. Facial involvement 
can mimic seborrhoeic dermatitis. Lesions may appear psoriasiform. 
Palmoplantar lesions are commonly hyperkeratotic. Lesions commonly 
are encountered without an active border, scaling and central clearing 
such as are found characteristically in the immunocompetent host 
(Figure 2).  Widespread dermatophytosis is not common in HIV/AIDS.  
Nodular perifolliculitis (Majocci’s granuloma) (Figure 3)  has been 
observed.  Dermatophyte infection of the nails, typically caused by 
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Trichophyton rubrum, in the non-HIV-infected individual occurs as 
distal and lateral subungual onychomycosis. In HIV-infected patients 
proximal white subungual onychomycosis (Figure 4) is characteristic, 
appearing as chalky, white proximal nail discolouration. This condition 
is rare in non-HIV-infected individuals. The finding of proximal white 
subungual onychomycosis is an indication for HIV serotesting. 
Figure 2:   Dermatophyte infection on the cheek.  An active border is only focally 
present
Figure 3:   Nodular perifolliculitis displaying verrucous morphology. Note the 
lymphadenopathy (arrows)
Figure 4: Proximal white subungual onychomycosis involving the first toe nails
Diagnosis of dermatophytosis is established by the demonstration 
of mycelia in a potassium hydroxide (KOH) preparation of lesional 
scrapings and isolation of the fungus on culture. 
Systemic treatment is indicated for widespread cutaneous involvement, 
tinea capitis and for involvement of several nails. Griseofulvin, 
ketoconazole, itraconazole and terbinafine are effective treatments. 
For localised involvement a topical imidazole preparation will usually 
suffice. 
3.  Candidiasis
 Oral candidiasis has classically been associated with 
immunosuppressive states and was one of the first features to be 
identified in the early days of the HIV epidemic. The prevalence of 
oral candidiasis in HIV patients ranges from 30–80% according to the 
population, the follow-up period and the level of immunodeficiency. 
The greater the level of immunodeficiency the more frequent the 
infection. Candidiasis is related to an unfavourable outlook for the 
patient. Mucosal candidiasis is a frequent HIV-associated opportunistic 
infection and its presence in an apparently healthy adult necessitates 
HIV serotesting. It is a consequence of overgrowth of a normal 
resident microorganism. Oropharyngeal candidiasis (Figure 5), the 
most common form, is often the initial manifestation of HIV-disease, 
and is a predictor of progression to AIDS. This condition is often 
asymptomatic, but soreness or burning of the mouth, or dysgeusia 
may be experienced. Five patterns of presentation are seen (Table 
III). Esophageal candidiasis may be asymptomatic or associated with 
retrosternal burning or odynophagia, and is an AIDS-defining condition 
typically affecting those with a CD4 count of less than 100. Candidiasis 
may also involve the lungs and bronchi.  In HIV-infected women, 
recurrent candidal vulvovaginitis occurs frequently and may be the 
initial clinical manifestation of HIV-disease. In young children with HIV-
disease, chronic candidal paronychia and nail dystrophy are frequent. 
Candida may cause intertrigo.  Recurrences of the infection following 
seemingly effective treatment are common. Diagnosis of candidiasis is 
made by the clinical presentation and demonstration of pseudomycelia 
on a KOH preparation of lesional scrapings. Culture is not helpful. 
Figure 5:  Erythematolous candidiasis involving the dorsal aspect of the tongue
Treatment options include topical nystatin or clotrimazole, and systemic 
ketoconazole, itraconazole, or fluconazole. Intravenous amphotericin B 
should be administered in refractory cases. 
4.  Herpes simplex virus 
 Herpes simplex virus (HSV) and varicella zoster virus (VZV) cause 
latent or recurrent infections of the skin and nerves. With HIV-
associated immune suppression, previously latent or mild infections 
may become severe. Both HSV and VZV infections are markers for 
unsuspected HIV infection and HIV serotesting should be considered. 
Genital herpes is a risk factor for transmission of HIV infection mainly 
through transfer of virus during sexual intercourse.  Herpes simplex 
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infection of longer than one month duration in HIV patients is an 
AIDS-defining condition.  Reactivated HSV infection is a common 
complication of HIV-disease. Frequent sites of infection include the 
anogenital area, face, oropharynx, and fingers. Periungual lesions 
(herpetic whitlow) and herpetic folliculitis on the face are frequently 
misdiagnosed as bacterial infections. In early HIV-disease, HSV 
infection has a classic presentation with grouped vesicles or erosions 
that heal in one to two weeks without treatment. With increasing 
immunodeficiency, painful enlarging ulcers with raised margins occur. 
Untreated these ulcers may enlarge and become confluent involving 
large areas of the face or anogenital region (Figure 6). When the CD4 
count are less than 50, 58% of all ulcerations and 67% of all perianal 
ulcerations contain HSV. Multiple scattered lesions in one area are 
not uncommon, but widespread dissemination of HSV is rare, even in 
patients with advanced HIV-disease. Spreading ulcers contiguous with 
herpetic vesicles of the lips may occur (Figure 7).  These ulcers are 
noninflammatory and a very high index of suspicion is necessary to 
make the correct diagnosis.  Moist plagues with seropurulent exudates 
(Figure 8), may appear in the anogenital area and lower back.  HSV 
infection is often non self-limiting.  Persistent necrotic digits have 
been described.  HSV can also infect the mucosa, producing proctitis, 
glossitis, oesophagitis, or severe gingivostomatitis, seen mainly in 
children. HSV should be considered in the differential diagnosis of 
any ulcerative or crusted lesion in a patient with HIV-disease. The 
presence of mucocutaneous HSV infection for longer than one month 
is suggestive of advanced HIV infection. 
Figure 6:   Multiple ulcers involving the anogenital region.  Note the depth of 
some ulcers.
The Tzanck smear and lesional skin biopsy are diagnostically useful 
but cannot distinguish between HSV and VZV infection. Specific 
diagnostic techniques include detection of specific HSV-1 and HSV-2 
antigens in exudates of tissue by direct fluorescent-antibody staining 
and the amplification of HSV DNA by PCR. Serologic tests are of no 
value in the diagnosis of cutaneous HSV infections. Isolation of HSV 
Figure 7:  Superficial herpetic ulcers of the upper lip and angle of the mouth
Figure 8:   HSV infection of the scrotum showing a moist, purulent plaque. 
Postinflammatory hypopigmentation is present at the site of a 
previous lesion
by culture enables viral typing and determination of antiviral drug 
susceptibilities. 
Treatment options include acyclovir, famciclovir and valaciclovir. Lack 
of response suggests infection with a resistant strain. Treatment with 
foscarnet should be considered in these cases. 
5.  Varicella-zoster virus 
Primary VZV infection (varicella) in HIV-disease can be severe 
(Figure 9), prolonged, and complicated by parenchymal infection 
such as pneumonia, bacterial superinfection, and death. HIV-infected 
individuals with previous varicella have a risk of reactivated VZV 
infection (herpes zoster), 17 times greater that of non-HIV-infected 
controls. Herpes zoster in any patient should raise the issue of 
HIV serotesting. Herpes zoster may be the initial manifestation of 
immunodeficiency, but can develop at any stage of HIV-disease 
and is not predictive of more rapid progression to AIDS. Herpes 
zoster appears more frequently in patients with low CD-4 counts.  
Herpes zoster typically presents as a painful, vesicular, erosive, 
dermatomal eruption which resolves uneventfully. With increasing 
immunodeficiency, it can also be multidermatomal (usually contiguous), 
ulcerated, disseminated, or recurrent, followed by postherpetic 
neuralgia and scarring. Lesions that persist for months after primary, 
reactivation, or disseminated VZV infection may appear as painful 
hyperkeratotic, ulcerated, or crusted nodules (Figure 10).  Folliculitis, 
verrucous dermatomal plaques and widespread ecthymatous necrotic 
lesions have been documented.  With marked immunocompromise 
Table III: Patterns of presentation of oropharyngeal candidiasis 
1.   Erythematous or atrophic – patches of erythema on the palate or 
atrophic areas on the tongue 
2.   Pseudomembranous – superficial, white flecks without 
surrounding inflammation 
3.   Hyperplastic – patchy hyperkeratosis on the dorsum of the 
tongue 
4.  Erosive / ulcerative – shallow defects of the mucosa covered with 
a seropurulent exudate
5.  Angular cheilitis – intertrigo at the angles of the lips 
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visceral dissemination, and CNS involvement such as encephalitis, 
meningitis, myelitis, and polyneuritis may develop. 
 
Figure 9:   Extensive varicella infection.  The patient also had varicella 
pneumonitis
Figure 10:  Hyperkeratotic persistent lesions in vericella.  Lesions still contained 
virus
The diagnosis of herpes zoster is made on clinical findings, assisted by 
a Tzanck smear, lesional biopsy, monoclonal antibody detection of VZV 
antigen in a smear of an exudate, and isolation of VZV- by viral culture. 
Patients with mild to moderate immunodeficiency can be treated with 
oral acyclovir (800 mg every 6 hours for 7 days). Those with advanced 
immunodeficiency, recurrent disease, or ophthalmic involvement 
should be treated with intravenous acyclovir. Famciclovir and 
valaciclovir are alternative therapeutic agents. If lesions do not respond 
within one to two weeks, foscarnet therapy should be considered. 
6.  Epstein-Barr virus 
 Oral hairy leukoplakia (OHL) is a benign lesion of the oral mucosa 
caused by replication of the Epstein-Barr virus. OHL has been detected 
in the majority of HIV-infected homosexual and bisexual males 
with moderate to advanced immunodeficiency. OHL has also been 
described in normal and in HIV-seronegative immunosuppressed 
patients. Nevertheless, OHL is particularly important because it is an 
early specific sign of HIV infection, with the sinister implication that 75% 
of patients develop AIDS within 2–3 years.  Lesions are asymptomatic, 
single or multiple, white or grey, corrugated plaques with characteristic 
vertical ridging (Figure 11). Lesions are typically found on the lateral 
and inferior surfaces of the tongue, but may extend to involve other 
parts of the tongue, the buccal mucosa and soft palate. In contrast with 
pseudomembranous candidiasis, OHL cannot be removed with a dry 
gauze or curette and usually does not respond to antifungal therapy.  
OHL is a clinical indicator of disease activity.  Trauma, lichen planus 
and white-sponge nevus should also be considered in the differential 
diagnosis.  
Figure 11:  Oral hairy leukoplakia involving the side of the tongue
Diagnosis is made on clinical grounds, but can be confirmed with 
biopsy. 
Topical podophyllin is reasonably effective in the treatment of OHL. 
Chronic systemic acyclovir is also beneficial, but lesions recur after 
discontinuation of treatment.   Recently oral famciclovir has been 
reported to be beneficial in the treatment of OHL.
7.  Molluscum contagiosum
 Lesions of molluscum contagiosum (MC) are caused by a large (200 
x 300 nm) double stranded DNA virus of the family Poxviridae which 
selectively infects human epidermal cells. The virus is transmitted via 
contact with infected skin. In the immunocompetent host, lesions are 
discrete, pearly, dome-shaped, often umbilicated papules of 3–10 mm 
in diameter, which eventually resolve spontaneously. In HIV-infected 
individuals, MC has a 5–18% prevalence and is a manifestation of 
moderate-to-advanced immunosuppression. Patients with numerous 
mollusca involving multiple sites have CD4 counts of less than 50, 
almost without exception (Figure 12). Patients present with multiple 
small, papules or nodules or large tumors, over 1 cm in diameter 
(Figure 13), most commonly arising on the face, especially the beard 
area, the neck, and intertriginous sites. Shaving is a major factor in 
the spread of mollusca. Lesions are commonly not dome shaped 
and the central umbilication is often absent.  These lesions cause 
significant morbidity because of the physical disfigurement and their 
potential to induce pruritus and eczematisation. Multiple facial lesions 
must be differentiated from the cutaneous lesions of disseminated 
cryptococcosis, histoplasmosis, coccidiodomycosis, and penicillinosis. 
The diagnosis is based on the distinctive clinical morphology aided 
by the expression of a white, curd like core. This core reveals 
characteristic viral inclusions (molluscum bodies) upon staining with 
toluidine blue or Giemsa stain. Lesional biopsy shows a downgrowth of 
epidermal cells containing molluscum bodies. 
Figure 12:  Numerous MC involving the fingers and buttocks
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Figure 13:  Giant MC and large confluent MC in a young child
Therapy is aimed at reducing the number of disfiguring lesions, 
but cure of the infection is difficult. Cryosurgery, curettage, 
electrodessication, and laser ablation are useful treatment options. 
Systemic therapy, including alpha interferon, is ineffective. 
8.  Scabies
  In early HIV-disease, scabies has a classic presentation with 
erythematous, pruritic papules and burrows in the finger webs, 
wrists, and anogenital region. With progressive immunodeficiency, 
individuals may develop either a diffuse papular eruption or 
hyperkeratotic, yellowish plaques on the scalp, face, hands, back, 
and trunk  (Figure 14) – keratotic scabies. Pruritus is minimal 
or absent. The number of infesting mites can increase into the 
millions, making this condition highly contagious. Excoriations 
can become secondarily infected, at times leading to septicaemia 
and death. Multiburrow scabies, featuring hundreds of burrows, 
associated with keratotic scabies of the skin folds occurred in 
a haemophiliac child who acquired HIV/AIDS through blood 
transfusion (unpublished personal observation).  
Figure 14:   Keratotic scabies involving the abdomen, forearm and hand.  
Lesions are plate-like, exophytic and/or glove-like
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Diagnosis is made by identification of mites, eggs, eggshells or faecal 
pellets in lesional skin scrapings or skin biopsy. 
Patients and household contacts should be treated with gamma 
benzene hexachloride or benzyl-benzoate.  Recurrence of keratotic 
scabies is common due to the large number of infesting organisms. 
Ivermectin may become the treatment of choice. 
9.  Kaposi’s sarcoma
Epidemic, or HIV-associated Kaposi’s sarcoma (KS), occurs in 
approximately 15% of individuals with AIDS. In the United States, KS 
is at least 20 000 times more common in HIV-infected individuals than 
in the general population, and 300 times more common than in other 
immunocompromised groups. Ninety-five percent of epidemic KS 
occurs in homosexual and bisexual men, an incidence much higher 
than in other risk groups. Human herpes virus-8 may be implicated in 
the pathogenesis of KS. 
The initial lesions of KS are asymptomatic, erythematous to violaceous, 
macules or papules. Lesions are commonly elongated and follow the 
lines of skin tension.  Enlarging lesions evolve into oval, violaceous 
nodules or plaques, typically involving the trunk (where their long axes 
may lie parallel to the skin lines), extremities, face, and oral cavity. 
Lesions may remain discrete or merge into large confluent masses. 
Cutaneous KS can cause significant cosmetic disfigurement, especially 
when present on the face. A second pattern of cutaneous involvement 
is lymphoedema, which can arise in association with a cluster of KS 
lesions, or result from proximal lymphatic obstruction. Lymphoedema 
is usually most pronounced on the distal extremities (Figures 15-16) 
and the face. Progressive lower limb oedema is often associated with 
significant pain, and may limit ambulation. Lymphostatic verrucous may 
develop.  The skin assumes a verrucous appearance which is related 
to reactive thickening of the skin.  Ulceration provides a portal of entry 
for secondary bacterial infection. Facial oedema may be severe, 
causing striking disfigurement.  Koebnerisation may be witnessed.  KS 
may also involve the oral mucosa (Figure 17), palate and genitalia.   
Lesions of KS can also arise in the gastrointestinal tract, lymph nodes, 
liver, lungs, spleen, and kidneys – even in the absence of cutaneous 
involvement.  
Diagnosis is made clinically and can be confirmed by skin biopsy. 
Local treatment options include intralesional vinblastine, radiotherapy, 
cryotherapy, or surgical excision. Systemic therapies for more 
extensive disease include chemotherapeutic agents such as 
vincristine, vinblastine, bleomycin, adriamycin, doxorubin, alpha 
interferon and zidovudine. 
Figure 15:   Kaposi sarcoma involving the foot and leg.  Extensive bony 
destruction may be present
10. HIV-associated eosinophilic folliculitis 
 Pruritus is one of the most common symptoms reported in patients 
with HIV disease.  Pruritus may develop in the absence of a skin rash 
or may be associated with a systemic or cutaneous disease.  Skin 
infections, dermatitis, (e.g. seborrhoeic dermatitis), xeroderma (dry 
skin), drug eruptions, insect bites, pruritic papular eruption, eosinophilic 
folliculitis, atopy, hepatitis B or C, renal failure and lymphoma may 
be associated with pruritus.  The diagnostic importance of pruritus 
is certainly underestimated.  Eosinophilic folliculitis (EF), is typically 
seen in HIV-infected individuals with a CD4 count less than 100. It 
has also been reported in HIV-seronegative individuals with immune 
dysregulation. EF is a chronic, extremely pruritic dermatosis. 
EF is characterised clinically by multiple reddish, oedematous, 
follicular papules arising on the face, neck (Figure 18), upper trunk, 
and proximal upper extremities. Pustules are occasionally seen. 
Excoriations and postinflammatory hyperpigmentation occur commonly 
secondary to chronic scratching. Photosensitivity may be present.  EF 
must be differentiated from staphylococcal folliculitis, Pityrosporum 
folliculitis, herpetic folliculitis, dermatophyte folliculitis, scabies, acne 
vulgaris, rosacea, papular urticaria and papular dermatitis. The cause 
of EF is not known.  A role for Dermodex folliculorum is controversial.  
IRIS EF has been described.  
Figure 16:   Plaques of kaposi sarcoma involving the back.  Patches and 
plaques are often elongated and follow the skin lines
Lesional skin biopsy is usually required to confirm the diagnosis and 
shows a perivascular and perifollicular mononuclear cell infiltrate 
with numerous eosinophils. Direct involvement of the hair follicle and 
associated sebaceous gland is usually present.  Peripheral eosinophilia 
is common. 
EF responds poorly to UVB phototherapy, antihistamines, potent 
topical corticosteroids, isotretinoin, and itraconazole. Systemic 
corticosteroids are effective but their use should be minimised 
because of their immunosuppressive action. Pruritic papular eruption 
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(PPE) develops in 10–45% of patients with HIV/AIDS. PPE is a sign 
of advanced immunsuppression occurring at CD4 counts below 
100–200. The cause of PPE is unknown, Hypersensitivity to insect 
bites is a speculative pathmechanism. In the author’s experience PPE 
is indistinguishable from papular urticaria in individuals who are HIV 
negative. Lesions occur on the trunk and limbs in the form of pruritic 
papules (Figure 19). The primary lesion is a reddish papule 1–4 mm 
in diameter. Because of intense pruritus secondary changes such as 
scratch marks, ulceration, eczematisation and secondary pyoderma 
are common. Histology shows perivascular lymphocytes and 
eosinophils. Follicular involvement is usually not a feature. PPE and EF 
are related conditions. Patients are quite commonly encountered who 
present with both conditions. The treatment of PPE is similar to that of 
EF. 
Figure 19:   Pruritic papular eruption involving the back.  The primary lesion is 
a pruritic, reddish papule
11.  Papulosquamous disorders
 Papulosquamous disorders occurring in the setting of HIV-disease 
are common.  Only 1–3% of the general population have seborrhoeic 
dermatitis.  Seborrhoeic dermatitis occurs in 20–85% of patients 
with HIV infection. The  incidence and severity increase with 
advancing immunodeficiency. Scaly, erythematous or yellowish 
patches typically involve the scalp, face, chest, back, axillae, or pubic 
area. These lesions can be confused with dermatophyte infection, 
lupus erythematosus or psoriasis.  Folliculitis has been reported.  
Erythroderma may occur.  The role of Malassezia organisms in the 
pathogenesis is controversial.  In early HIV-disease, seborrhoeic 
dermatitis responds to treatment with topical corticosteroids and 
Figure 17:  Extensive involvement of the gingiva by Kaposi’s sarcoma
Figure 18:   Eosinophylic folliculitis involving the face and neck.  Comedones 
are absent
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ketoconazole cream or shampoo. Oral antifungal agents prescribed 
for fungal infections may inadvertently control seborrhoeic dermatitis. 
Resistance to treatment characterises advanced HIV-disease. 
Widespread seborrhoeic dermatitis (Figure 20), resistant to treatment, 
is an indication for HIV serotesting. Seborrhoeic dermatitis is found 
at every stage of HIV disease.  The frequency, duration and severity 
of the dermatitis correlates with the degree of immunsuppression.  
Severe, widespread seborrhoeic dermatitis indicates deterioration of 
the underlying immunological disorder.  
Acquired ichthyosis occurs commonly in patients with advanced 
HIV-disease. The condition involves the trunk and limbs and is 
characterised by dry, scaly skin. Emollients provide considerable relief 
of symptoms.  
Xerosis refers to dryness of the skin without scaling.  Xerosis is 
common in HIV disease.  Pruritus is often associated.  Treatment is 
with emollients.  
The prevalence of psoriasis in HIV-seropositive individuals is similar 
to that in the general population. Psoriasis may initially present 
shortly after HIV seroconversion and be the first manifestation of HIV 
disease.  De novo appearance of psoriasis or sudden worsening of 
pre-existing lesions in a person with high-risk sexual behaviour is an 
indication for undertaking an HIV test.  With advanced HIV-disease, 
mild preexisting psoriasis may become exacerbated and resistant to 
therapy. Individuals typically develop discrete, red, scaly plaques or a 
more diffuse hyperkeratotic dermatitis associated with palmoplantar 
keratoderma. Guttate psoriasis, inverse psoriasis and erythroderma 
may develop.  Severe onychodystrophy is not uncommon.  Psoriasis 
tends to worsen as immunodeficiency advances.  Lesions may 
respond to antiretroviral treatment with zidovudine or more 
conventional therapies such as topical corticosteroids, anthralin, 
tar, phototherapy, or etretinate. Widespread disease can be difficult 
to control and potentially immunosuppressive agents such as 
methotrexate and cyclosporin should be used with caution. There may 
be a 10 to 20 times higher prevalence of psoriatic arthritis and a 100 
times higher prevalence of Reiter’s syndrome.   Reiter’s syndrome 
(arthritis, urethritis and conjunctivitis) displays psoriasiform skin 
lesions, palmoplantar keratoderma and circinate balanitis/vulvitis.  
Reiter’s syndrome has been described in the setting of HIV disease 
and involvement is commonly severe.  Atopic dermatitis or an atopic 
dermatitis-like condition appears to be common in children in HIV 
disease.  Others believe that atopic dermatitis is not affected by HIV 
infection.  The existence of an HIV-associated dermatitis, independent 
of other types of dermatitis, is controversial.
12. Adverse cutaneous drug eruptions
 The incidence of cutaneous drug eruptions is greatly increased in 
HIV-disease and correlates with the decline and dysregulation of 
immune function (Figure 21). Between 50–60% of patients with AIDS 
treated with trimethoprim-sulfamethoxazole develop a morbilliform 
eruption one to two weeks after commencing therapy. This rash 
reaches maximal intensity one to two days after its initial appearance, 
and rapidly resolves with discontinuation of the drug. Other drugs 
associated with an increased incidence of cutaneous reactions include 
sulfadiazine and the aminopenicillins. The incidence of toxic epidermal 
necrolysis and Stevens-Johnson syndrome is also increased in HIV-
disease. The most common causative agents in this population are 
sulfonamides. Treatment of cutaneous drug eruptions necessitates 
discontinuation of the offending agent and supportive and symptomatic 
treatment.  A discussion of the cutaneous side effects of the 
antiretroviral and other drugs such as TB drugs, and drug interactions 
are beyond the scope of this manuscript.    
Figure 21:   Drug eruptions may be mild e.g. morbilliform erythema or severe 
e.g. Stevens Johnson syndrome
Figure 20:   Extensive seborrhoeic dermatitis of the chest and back.  Note some 
resemblance to a dermatophytic insection (arrows)
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It is important to know the skin and mucosal manifestations of HIV/
AIDS.  The diagnosis is commonly difficult.  In most cases a diagnosis 
can be made, treatment commenced and the quality of life of the 
patient improved.
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Launch of Fexaway tablets
Adcock Ingram is pleased to announce the launch of Fexaway tablets 
to be sold by the Restan division. 
It is available as Fexaway 120 mg tablets 10’s and Fexaway 180 mg 
tablets 30’s. They both contain Fexofenadine hydrochloride, a second 
generation antihistamine which lacks sedative effects. Fexaway 
120 mg is indicated for the relief of symptoms of seasonal allergic 
rhinitis and the Fexaway 180 mg for the relief of symptoms of chronic 
idiopathic urticaria.
Fexaway has a convenient once daily dosage for adults and children 
over the age of 12. Fexaway is available at a competitive price with 
significant savings to the patient vs. the original product1.
For more information contact Marjolein Bench on 011 635 0000
Ref 1. http://www.pbb.co.za/
 S2 FEXAWAY 120. A 5.7.1. Each tablet contains Fexofenadine 
hydrochloride 120 mg Reg. No. 41/5.7.1/0133
 S2 FEXAWAY 180. A 5.7.1. Each tablet contains Fexofenadine 
hydrochloride 180 mg Reg. No. 41/5.7.1/0134
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Marketed by Adcock Ingram Healthcare (Pty) Ltd. Reg. No. 2007/
019928/08 on behalf of Dr Reddy’s Laboratories SA (Pty) Ltd. Private 
Bag X69, Bryanston, 2021. Tel (011) 635 0000
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